Clinical study of ribavirin combined with compound lactobacillus acidophilus in the treatment of children with rotavirus enteritis

doi:10.3877/cma.j.issn.2095-2015.2024.04.016

Abstract

Abstract:

Objective

To explore the therapeutic effect of ribavirin combined with compound lactobacillus acidophilus on children with rotavirus enteritis (RVE) and its effects on serum advanced glycation end products (AGEs), inflammatory factors, and intestinal microbiota.

Methods

A total of 100 children with RVE in Jieshou City People's Hospital from March 2019 to November 2023 were selected. They were divided into a control group (compound lactobacillus acidophilus, n=50) and an observation group (ribavirin+compound lactobacillus acidophilus, n=50) using a random number table method. The clinical efficacy, serum AGEs and inflammatory factor levels, gut microbiota levels, intestinal mucosal barrier indicators and gastrointestinal hormones, as well as the conversion of rotavirus to negative and medication safety between the two groups were compared.

Results

The clinical efficacy of the observation group was higher than that of the control group (94.54% vs. 81.81%, P<0.05). The levels of AGEs and inflammatory factors in the observation group were lower than those in the control group (both P<0.05). The numbers of Escherichia coli and Enterococcus in the observation group was lower than those in the control group, while the numbers of Lactobacillus and Bifidobacterium were higher than those in the control group (both P<0.05). The intestinal mucosal barrier indicators and gastrointestinal hormone levels in the observation group were lower than those in the control group (both P<0.05). The negative conversion rate of rotavirus in the observation group was higher than that in the control group (92.00% vs. 78.00%, P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (8.00% vs. 12.00%, P>0.05).

Conclusion

The combination of ribavirin and compound lactobacillus acidophilus can significantly alleviate symptoms, regulate the levels of intestinal flora, serum AGEs and inflammatory factor levels, with good safety.

Key words: Rotavirus enteritis, Ribavirin, Compound lactobacillus acidophilus, Advanced glycation end products, Inflammatory factors, Intestinal microbiota

Xiuling Li, Shaofeng Lian, LiuTao Rong, Dengfeng Li, Yunyu Rao. Clinical study of ribavirin combined with compound lactobacillus acidophilus in the treatment of children with rotavirus enteritis[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(04): 369-372.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2024.04.016

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2024/V14/I04/369

Figures/Tables 5

References 15

[1]	邓有敬, 丁伟, 张芳玲, 等. 清热利湿方联合布拉氏酵母菌治疗儿童轮状病毒性肠炎效果及对血清AGEs、IL-6及NT-proBNP的影响[J]. 中国病原生物学杂志, 2022, 17(4): 451-454, 458.
[2]	黄欢娣. 重组人干扰素α-1b联合利巴韦林对重症手足口病患儿症状改善及血清细胞因子水平的影响[J]. 中国药物与临床, 2021, 21(23): 3869-3871.
[3]	孙强, 宋维亮. 新型冠状病毒肺炎对肠道微生物群及肠黏膜屏障缺陷影响机制的研究进展[J]. 天津医药, 2023, 51(1): 105-108.
[4]	吴可, 苏鹏飞, 佟延新. 美沙拉秦联合双歧杆菌嗜酸乳杆菌肠球菌三联活菌治疗溃疡性结肠炎效果及对患者血清sRAGE、Vaspin、炎性因子等影响[J]. 临床误诊误治, 2020, 33(2): 37-42.
[5]	陈彩华, 钟丽花, 朱道谋. 布拉酵母菌散联合蒙脱石散对轮状病毒性肠炎患儿的疗效、免疫功能及肠道微生态影响[J/OL]. 中华妇幼临床医学杂志(电子版), 2021, 17(6): 732-739.
[6]	孙蓓蓓, 封东进, 王光猛, 等. 葡萄糖酸锌颗粒联合消旋卡多曲颗粒对轮状病毒性肠炎患儿血浆炎性因子、心肌酶指标及免疫功能的影响[J]. 现代生物医学进展, 2020, 20(23): 4543-4546, 4551.
[7]	刘丽君, 程莹. 消旋卡多曲与秋泻灵颗粒联合肠道微生态调节剂治疗轮状病毒性肠炎疗效及对患儿外周血T淋巴细胞亚群水平的影响[J]. 陕西医学杂志, 2020, 49(8): 1013-1015, 1039.
[8]	韩玲琳, 张晓, 丁婷燕. 布拉酵母菌辅助治疗小儿轮状病毒性肠炎的疗效及对患儿肠道菌群的影响[J]. 中国妇幼保健, 2021, 36(6): 1318-1321.
[9]	江萍, 胡敏, 李斌. 葡萄糖酸锌联合消旋卡多曲对轮状病毒性肠炎患儿机体微炎症状态及肠黏膜屏障功能的影响[J]. 中南医学科学杂志, 2021, 49(3): 318-321.
[10]	Tejada S, Martinez-Reviejo R, Karakoc HN, et al. Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: A Systematic Review and Meta-Analysis[J]. Adv Ther, 2022, 39(9): 4037-4051.
[11]	王立东, 张玉霞, 王茜. 维生素B2联合双歧杆菌乳杆菌三联活菌和蒙脱石散治疗小儿轮状病毒性肠炎的临床研究[J]. 现代药物与临床, 2021, 36(2): 355-358.
[12]	Adiningrat A, Kusnadi RA, Allam AS, et al. The Effect of Probiotic Lactobacillus acidophilus and Ethanolic Propolis Compound toward Nucleic Acid Deposition in the Extracellular Polymeric Substance of Root Canal Bacteria[J]. Eur J Dent, 2023, 17(2): 418-423.
[13]	蔡露良, 林涛, 钟广会, 等. 重组人干扰素α-1b用于小儿轮状病毒感染性肠炎对肠功能的保护作用[J]. 临床和实验医学杂志, 2020, 19(18): 1994-1998.
[14]	陈方, 陈全景. 轮状病毒性肠炎伴心肌损伤危险因素探讨及风险列线图模型的建立[J]. 中国医师进修杂志, 2020, 43(12): 1101-1105.
[15]	王刚祚, 姚宝珍. 罗伊氏乳杆菌对小儿轮状病毒感染肠炎的疗效及其对患儿肠道菌群与胃肠激素的影响[J]. 川北医学院学报, 2022, 37(1): 47-50.

组别	例数	显效	有效	无效	总有效率
观察组	50	20(40.00)	25(54.54)	5(5.45)	45(94.54)^*
对照组	50	18(36.36)	19(45.45)	13(18.18)	37(81.81)

组别	例数	显效	有效	无效	总有效率
观察组	50	20(40.00)	25(54.54)	5(5.45)	45(94.54)^*
对照组	50	18(36.36)	19(45.45)	13(18.18)	37(81.81)

组别	例数	AGEs(ng/L)		IL-8(ng/L)		TNF-α(ng/L)		hs-CRP(mg/L)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	50	357.42±25.56	188.64±16.79^*	80.41±15.33	38.62±29.77^*	60.61±11.65	26.22±6.33^*	21.33±4.22	8.78±2.67^*
对照组	50	358.11±25.67	200.17±18.16^*	80.33±15.18	463.65±10.32^*	58.88±11.23	30.08±7.83^*	21.25±4.16	10.11±3.01^*
t		0.126	3.094	0.240	2.348	0.707	0.552	0.890	2.196
P		0.899	0.002	0.980	0.021	0.481	0.012	0.928	0.030

组别	例数	AGEs(ng/L)		IL-8(ng/L)		TNF-α(ng/L)		hs-CRP(mg/L)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	50	357.42±25.56	188.64±16.79^*	80.41±15.33	38.62±29.77^*	60.61±11.65	26.22±6.33^*	21.33±4.22	8.78±2.67^*
对照组	50	358.11±25.67	200.17±18.16^*	80.33±15.18	463.65±10.32^*	58.88±11.23	30.08±7.83^*	21.25±4.16	10.11±3.01^*
t		0.126	3.094	0.240	2.348	0.707	0.552	0.890	2.196
P		0.899	0.002	0.980	0.021	0.481	0.012	0.928	0.030

组别	例数	大肠埃希菌		乳酸杆菌		双歧杆菌菌		肠球菌
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	50	8.14±1.57	6.47±1.44^*	7.75±1.83	10.52±2.23^*	7.55±1.72	8.93±2.13^*	9.25±1.77	7.13±1.55^*
对照组	50	8.16±1.59	7.22±1.51^*	7.81±1.92	8.92±2.17^*	7.58±1.83	7.74±2.01^*	9.33±1.83	8.02±1.67^*
t		0.593	2.384	0.150	3.405	0.792	2.688	0.208	2.592
P		0.952	0.019	0.881	0.001	0.937	0.008	0.835	0.011

Please choose a citation manager

Content to export